Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Futuximab/modotuximab (Primary) ; Capecitabine; Fluorouracil
- Indications Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors EMD Serono; Merck KGaA; Symphogen
- 02 Aug 2017 The trial has been completed in Belgium (End Date:13-06-2014)
- 27 Jul 2017 The trial has been completed in Poland according to European Clinical Trials Database record.
- 25 Jul 2017 The trial has been completed in Spain according to European Clinical Trials Database record.